Kurma Partners et al. in €19m series-B for Horama

The series-B round of funding was led by Kurma.

This financing round follows the €4m series-A raised in July 2016, supported by Omnes, Sham and Go Capital. Initial seed investments totalling €800,000 took place in 2014 and 2015.

The new funding will finance the development of the Hora-PDE6B project, including the start of its clinical phase, which was recently authorised by the French regulatory bodies.

Company
Horama is a biotechnology company founded in March 2014 as a spinout from Inserm. Its gene therapy products treat inherited retinal dystrophies using recombinant adeno-associated viral (rAAV) vectors.

People
Horama – Denis Cayet (chair); Christine Placet (CEO).
Kurma Partners – Thierry Laugel (managing partner).
Fund+ – Philippe Monteyne (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• Venture